COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #12 of 230
4/14 Late treatment study
Tang et al., BMJ 2020, 369, doi:10.1136/bmj.m1849 (Peer Reviewed)
Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial
Source   PDF   Share   Tweet
150 patients very late stage RCT showing no significant difference. Treatment very late, average 16.6 days after symptom onset.
Data favorable to HCQ was deleted in the second version, see analysis [1]. "[HCQ] accelerate[s] the alleviation of clinical symptoms"; "More rapid alleviation of clinical symptoms with SOC plus HCQ than with SOC alone was observed during the second week since randomization"; "The efficacy of HCQ on the alleviation of symptoms, HR 8.83 [1.09-71.3], was more evident when the confounding effects of other anti-viral agents were removed"

Tang et al., 4/14/2020, Randomized Controlled Trial, China, Asia, peer-reviewed, 24 authors.
risk of no virological cure at day 21, 21.4% lower, RR 0.79, p = 0.51, treatment 11 of 75 (14.7%), control 14 of 75 (18.7%).
Details of all 230 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit